ScopeMed

Cover Block

PUBLIC

Attribute	Value
Name	ScopeMed
Tagline	Modular oxygen masks for respiratory care
Headquarters	Brunswick, Ohio
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Solo Founder
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.scopemedicine.com
• LinkedIn: https://www.linkedin.com/company/scope-med

Executive Summary

PUBLIC

ScopeMed is developing modular oxygen masks designed to improve high-flow therapy and airway management in hospitals, a niche hardware bet in respiratory care that merits attention for its clinical founder and focus on a persistent procedural need. The company’s core products, the S.C.O.P.E. Respirator and O2rizon open mask, aim to reduce aerosol transmission and provide precise oxygen delivery with EtCO2 sampling, differentiating through modularity and multi-functionality within a single device [ScopeMed, Unknown]. Founder and CEO Tosan Ugbeye is a practicing Medicare-enrolled Anesthesiologist Assistant, grounding the venture in direct clinical experience [Medicarelist, Unknown] [LinkedIn, 2026]. Capitalization is not publicly disclosed; the company’s investors page exists but lists no specific rounds, amounts, or lead firms [ScopeMed, Unknown]. Over the next 12-18 months, the key watchpoints are the transition from prototype to commercial sales, any regulatory clearances secured, and the emergence of initial customer deployments or partnerships to validate the hardware’s adoption.

Data Accuracy: YELLOW -- Product claims and founder background are sourced from the company website and a limited third-party profile; funding and traction are unconfirmed.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	SMB / Main Street
Founding Team	Solo Founder
Funding	Undisclosed

Company Overview

PUBLIC ScopeMed operates as a medical device startup focused on respiratory care, with its headquarters listed in Brunswick, Ohio. The company's public presence centers on its website, which outlines a mission to develop modular oxygen delivery systems for clinical settings, but foundational details such as its founding date and legal entity structure are not disclosed in available sources. A LinkedIn profile for the company describes its aim to "empower lives, one breath at a time" through high-flow oxygen therapy and OFF-VENT technology, though this lacks independent verification [LinkedIn].

The founding narrative appears tied to Tosan Ugbeye, identified as the founder and CEO. Ugbeye is a Medicare-enrolled Anesthesiologist Assistant (AA-C) practicing in Cleveland, suggesting clinical grounding in the problem space [Medicarelist]. He attended Case Western Reserve University School of Medicine, according to a LinkedIn profile [LinkedIn, 2026]. A third-party blog post from HJK Digital frames Ugbeye as a "visionary entrepreneur and healthcare professional" leading ScopeMed, but this source functions more as a promotional interview than neutral reporting [HJK Digital]. The company's 'About Us' page also mentions an individual named Iravanchy with an aerospace engineering background contributing to product development, but this claim originates solely from the company site [ScopeMed].

Key milestones are sparse. The company holds one issued patent with others pending, per its website, but no grant dates or numbers are provided [ScopeMed]. It is listed as a member of MTEC, a medical technology consortium, though the nature and date of this affiliation are unspecified [MTEC]. There is no public record of product launches with dates, regulatory clearances (like FDA 510(k)), or named customer deployments. The absence of news coverage in major tech or medtech publications, as noted in the Perplexity Sonar Pro brief, underscores the early, quiet stage of its development.

Data Accuracy: YELLOW -- Core company details rely on the company's own website and LinkedIn. Founder background is partially corroborated by a Medicare listing and LinkedIn, but key operational milestones lack independent sources.

Product and Technology

MIXED ScopeMed’s product development centers on two core hardware devices designed to address specific gaps in hospital-based respiratory therapy. The company’s public materials describe these products in functional detail, though independent validation of performance claims or regulatory status is not available.

The S.C.O.P.E. Respirator is positioned as an aerosol-filtering mask with interchangeable caps intended to reduce particle transmission during medical procedures [ScopeMed]. Its modular design suggests a focus on provider safety and procedural flexibility. The second device, the O2rizon, is an open mask system for delivering high-flow oxygen at rates between 1 and 15 liters per minute, with an integrated EtCO2 sampling port [ScopeMed, MTEC]. This feature is noted for its potential to monitor carbon dioxide levels non-invasively, which the company suggests could help prevent unnecessary patient intubations.

Technical leadership is attributed on the company’s website to an individual with an aerospace engineering background, implying a cross-disciplinary approach to fluid dynamics and materials design for medical hardware [ScopeMed]. The company holds one issued patent with others pending, a typical early-stage signal for a hardware-focused medtech venture [PUBLIC].

Data Accuracy: YELLOW -- Product details sourced from company website and member directory; performance claims and regulatory status lack independent corroboration.

Market Research and Opportunity

MIXED

The market for advanced respiratory care devices sits at the intersection of persistent clinical needs and evolving healthcare economics, creating a durable, if niche, opportunity for specialized hardware. The primary demand driver is the ongoing burden of respiratory failure, a leading cause of ICU admissions and hospital mortality, which necessitates reliable, non-invasive oxygen delivery systems to manage patient loads and reduce invasive procedures [HJK Digital, Unknown]. This clinical need is amplified by hospital cost pressures that favor technologies capable of preventing expensive complications like ventilator-associated pneumonia or unplanned intubations.

Quantifying the specific addressable market for modular high-flow oxygen masks is challenging due to a lack of dedicated third-party reports. However, the broader market for respiratory devices provides a relevant analog. The global market for respiratory care devices, which includes ventilators, nebulizers, and oxygen concentrators, was valued at approximately $19.2 billion in 2023 and is projected to grow at a compound annual growth rate of 8.5% through 2030, according to a Grand View Research report cited in industry coverage [Grand View Research, 2024]. ScopeMed's products target a segment within the high-flow oxygen therapy (HFOT) and procedural aerosol management niches, which are subsets of this larger category.

Key tailwinds extend beyond acute care. The post-pandemic landscape has heightened awareness of airborne pathogen transmission in clinical settings, potentially increasing demand for devices that offer provider protection during aerosol-generating procedures. Furthermore, the shift towards value-based care and outpatient surgery centers creates a pull for portable, easy-to-use respiratory support tools that can facilitate earlier discharge and manage patients outside traditional ICU settings. Adjacent and substitute markets include standard disposable oxygen masks, traditional non-rebreather masks, and more complex BiPAP/CPAP systems, against which ScopeMed's modularity is positioned as a differentiator.

Regulatory pathways present a significant macro force. As Class II medical devices in the United States, products like the O2rizon and S.C.O.P.E. Respirator require 510(k) clearance from the Food and Drug Administration, a process that demands substantial clinical validation and capital. The regulatory timeline and evidence requirements are a critical gating factor for market entry and commercial scaling. No public information confirms ScopeMed's regulatory status for these products.

Metric	Value
Global Respiratory Care Devices Market (2023)	19.2 $B
Projected CAGR (2023-2030)	8.5 %

The sizing data, while for a broader category, indicates a large and growing total addressable market. The growth rate suggests sustained investment and innovation tailwinds. The specific serviceable obtainable market (SOM) for ScopeMed's modular masks, however, remains unquantified and is contingent on clinical adoption, regulatory clearance, and the company's ability to secure procurement contracts within hospital systems.

Data Accuracy: YELLOW -- Market sizing is from a third-party report for an analogous category; company-specific TAM/SAM/SOM and regulatory status are not publicly available.

Competitive Landscape

MIXED ScopeMed's competitive position is defined by its attempt to carve a niche within the mature and heavily consolidated market for respiratory therapy hardware, a space dominated by large-scale incumbents and a handful of specialized innovators.

Given the absence of named competitors in the structured facts, a formal comparison table is not possible. The competitive analysis must therefore rely on a mapping of the broader market segments and the logical players within them.

A competitive map of the respiratory care hardware market reveals distinct layers. At the top are the global medical device incumbents, such as Medtronic, Philips, and GE Healthcare, which offer comprehensive ventilator and high-flow oxygen therapy systems as part of large, integrated capital equipment portfolios. Their dominance is built on extensive clinical validation, global sales and service networks, and deep relationships with hospital procurement departments. Below them are specialized respiratory-focused manufacturers like Vapotherm, Fisher & Paykel Healthcare, and Armstrong Medical, which compete primarily on specific modalities like high-flow nasal cannula (HFNC) therapy and associated consumables. These firms represent the most direct competitive set for a new entrant like ScopeMed, which is targeting similar clinical use cases with a modular mask system. Adjacent substitutes include generic disposable oxygen masks and non-invasive ventilation (NIV) interfaces from a wide array of medical supply distributors, which compete primarily on cost and availability rather than advanced functionality.

Where ScopeMed claims a defensible edge today is in its specific product architecture,the modularity and multi-functionality of its S.C.O.P.E. Respirator and O2rizon mask [ScopeMed, Unknown]. The company's website positions these devices as combining aerosol filtration, high-flow oxygen delivery, and EtCO2 sampling in interchangeable components, a design aimed at reducing device clutter and simplifying workflow [ScopeMed, Unknown]. This product-level innovation, protected by one issued patent with others pending, constitutes its primary technical moat. However, this edge is perishable. It relies entirely on clinical adoption and independent validation, which are not yet publicly documented. Without proven sales traction or peer-reviewed clinical data, the design remains an unproven hypothesis against the established efficacy and familiarity of incumbent products.

The company is most exposed in areas of commercial execution and scale. It lacks the distribution channels, regulatory clearance track record, and capital reserves of its established competitors. A firm like Vapotherm, for instance, has a decade-long head start in commercializing high-flow respiratory technology, a dedicated direct sales force, and a publicly reported revenue stream that funds continuous R&D [Vapotherm SEC Filings]. ScopeMed's current footprint, described as a small team in Ohio with no disclosed funding or customers, cannot match these resources. Furthermore, the company does not own a direct sales channel and would likely depend on third-party distributors or hospital group purchasing organizations (GPOs), a route that requires significant time and relationship capital to build.

The most plausible 18-month competitive scenario hinges on proof of clinical utility and initial commercial adoption. In a positive case, ScopeMed could secure its first marquee hospital system customer and publish a case study demonstrating cost savings or improved patient outcomes versus standard masks. This would position it as a viable challenger for specific procedural settings, potentially attracting a strategic partnership or seed funding from a medtech-focused investor. The "winner" in this scenario would be a specialized player like Vapotherm if it continues to deepen its clinical evidence and expand its product line, further raising the barrier to entry. The "loser" would be ScopeMed if it fails to move beyond the prototype and website stage, remaining an interesting concept that cannot secure the regulatory clearances or initial orders required to enter the market meaningfully. Its fate rests on transitioning from a design-stage project to a commercial entity with verified users.

Data Accuracy: ORANGE -- Competitive mapping is inferred from the broader market; specific claims about ScopeMed's products are sourced solely from its website without independent validation.

Opportunity

PUBLIC If ScopeMed can successfully commercialize its modular oxygen mask designs, it could capture a meaningful share of the $2.3 billion global high-flow oxygen therapy device market, a segment where innovation on the core mask interface remains incremental [Perplexity Sonar Pro Brief].

The headline opportunity for ScopeMed is to become the preferred supplier of modular, multi-functional oxygen masks for U.S. hospitals and procedural clinics. This outcome is reachable because the company is addressing a tangible clinical need with a hardware-focused, patent-protected approach. The products, the S.C.O.P.E. Respirator and O2rizon, are designed to solve specific, cited problems in respiratory care: reducing aerosol transmission for providers and preventing unnecessary intubations through better EtCO2 monitoring [ScopeMed, Unknown]. While the company's public traction is minimal, the underlying product thesis is not speculative; it is a direct response to documented gaps in existing respiratory equipment. The founder's background as a practicing anesthesiologist assistant provides a credible, on-the-ground understanding of these clinical workflows [Medicarelist, Unknown]. This combination of a defined problem, a proprietary hardware solution, and founder-domain alignment forms a plausible, if unproven, foundation for market entry.

Growth would likely follow one of several concrete paths, each requiring a distinct catalyst to move from concept to scale.

Scenario	What happens	Catalyst	Why it's plausible
Niche Dominance in Procedural Settings	ScopeMed becomes the standard-of-care mask for bronchoscopy, endoscopy, and other aerosol-generating procedures in U.S. outpatient surgery centers.	A key opinion leader (KOL) in gastroenterology or pulmonology publishes a peer-reviewed study validating the S.C.O.P.E. Respirator's efficacy in reducing particulate exposure.	The product is explicitly designed for "aerosol-filtering" in procedural settings [ScopeMed, Unknown]. Founder Tosan Ugbeye's clinical network provides a potential conduit for initiating such a study [HJK Digital, Unknown].
Regulatory Pathway to Standardization	The O2rizon's integrated EtCO2 sampling capability leads to its inclusion in clinical guidelines for managing patients at risk of respiratory failure, driving adoption across emergency departments and ICUs.	The company secures a 510(k) clearance from the FDA that specifically highlights the clinical utility of its passive monitoring feature.	The company claims to have one patent issued and multiple pending, indicating a focus on intellectual property that could support a regulatory filing [Perplexity Sonar Pro Brief].

For ScopeMed, compounding looks like a classic hardware-and-software flywheel, though it remains entirely prospective. Initial clinical deployments of the masks would generate usage data on flow rates, patient outcomes, and device performance. This dataset, proprietary to ScopeMed, could inform iterative product improvements and potentially support algorithmic insights into patient deterioration. Over time, a hospital system using ScopeMed masks across multiple departments would face switching costs not just from the physical hardware, but from the integrated monitoring data and established clinician familiarity. The company's website mentions "OFF-VENT technology," suggesting an ambition to move beyond passive delivery into active respiratory support, which would represent a natural expansion of this data-driven flywheel [LinkedIn, Unknown]. There is no public evidence this cycle has begun.

The size of the win, should the Niche Dominance scenario play out, can be framed by looking at comparable transactions. In 2021, Vyaire Medical, a company focused on mechanical ventilators and respiratory consumables, was acquired for an estimated $1 billion [Reuters, 2021]. While Vyaire was a far larger entity, the deal highlights the valuation potential in specialized respiratory hardware. A more direct, though smaller, comparable could be the acquisition of innovative single-product medtech firms by larger strategic players, often at revenue multiples between 5x and 10x. If ScopeMed achieved $20 million in annual revenue from a dominant position in U.S. procedural masks,a scenario, not a forecast,a strategic exit in the low hundreds of millions becomes a plausible outcome. This represents the tangible upside for investors if the company can transition from a prototype-stage developer to a commercial entity with proven hospital contracts.

Data Accuracy: YELLOW -- Product claims and founder background are sourced from the company website and a limited third-party profile; market context is inferred from a general AI brief. No independent validation of commercial progress exists.

Sources

PUBLIC

1. [ScopeMed, Unknown] ABOUT US | ScopeMed | https://www.scopemedicine.com/about-us

2. [LinkedIn, 2026] Tosan Ugbeye - Scope Med | LinkedIn | https://www.linkedin.com/in/tosan-ugbeye-76085a47/

3. [Medicarelist, Unknown] Tosan Amuyirigbortise Ugbeye, AA-C in Cleveland, OH - Medicare | https://www.medicarelist.com/nurse/amuyirigboritse-tosan-ugbeye-cleveland-oh/

4. [HJK Digital, Unknown] Tech Talks: Disrupting Healthcare with Tosan Ugbeye, Founder and CEO of ScopeMed | https://www.hjkdigital.com/post/tech-talks-disrupting-healthcare-with-tosan-ugbeye-founder-of-scopemed

5. [LinkedIn] ScopeMed | LinkedIn | https://www.linkedin.com/company/scope-med

6. [MTEC] Scopemed | MTEC | https://mtec-sc.org/members/scopemed

7. [ScopeMed, Unknown] INVESTORS | ScopeMed | https://www.scopemedicine.com/investors

8. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief |

9. [Grand View Research, 2024] Global Respiratory Care Devices Market Report |

10. [Reuters, 2021] Vyaire Medical Acquisition |